| Dr Mark Bernard Lubienski, MD | |
|
372 Red Bud Ct, Frankfort, IL 60423-2128 | |
| (708) 710-6048 | |
| (815) 464-1984 |
| Full Name | Dr Mark Bernard Lubienski |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery |
| Experience | 40 Years |
| Location | 372 Red Bud Ct, Frankfort, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376543025 | NPI | - | NPPES |
| 036071444 | Medicaid | IL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 036071444 (Illinois) | Primary |
| 208G00000X | Thoracic Surgery (cardiothoracic Vascular Surgery) | 036071444 (Illinois) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Central Dupage Hospital | Winfield, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Advanced Woundcare, Inc | 3678971389 | 9 |
News Archive
Heart attack patients given a combination of high-dose oral vitamins and minerals do not exhibit a significant reduction in recurrent cardiac events, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
The report by scientists of a new hepatitis virus earlier this year was a false alarm, according to UC San Francisco researchers who correctly identified the virus as a contaminant present in a type of glassware used in many research labs.
Dr. [Ronald] Sroka has practiced family medicine for 32 years in a small, red-brick building just six miles from his childhood home. ... Dr. Sroka, 62, thought about retiring. He tried to sell his once highly profitable practice. No luck. He tried giving it away. No luck. Dr. Sroka's fate is emblematic of a transformation in American medicine. ... [D]octors like him are increasingly being replaced by teams of rotating doctors and nurses who do not know their patients nearly as well. A centuries-old intimacy between doctor and patient is being lost.
Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced interim data from a 12-week phase IIb clinical trial of IDX184, the Company's lead product candidate for the treatment of hepatitis C virus (HCV) infection.
Every principal investigator (PI) who uses laboratory animals in his or her research now can benefit from a new monthly independent source of expert advice in complying with government and institutional rules and ethics guidelines. That's the purpose of the new subscription newsletter, Laboratory Animal Welfare Compliance.
› Verified 9 days ago
| Entity Name | Onsite Healthcare Inc Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740585579 PECOS PAC ID: 1153505565 Enrollment ID: O20110408000722 |
News Archive
Heart attack patients given a combination of high-dose oral vitamins and minerals do not exhibit a significant reduction in recurrent cardiac events, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
The report by scientists of a new hepatitis virus earlier this year was a false alarm, according to UC San Francisco researchers who correctly identified the virus as a contaminant present in a type of glassware used in many research labs.
Dr. [Ronald] Sroka has practiced family medicine for 32 years in a small, red-brick building just six miles from his childhood home. ... Dr. Sroka, 62, thought about retiring. He tried to sell his once highly profitable practice. No luck. He tried giving it away. No luck. Dr. Sroka's fate is emblematic of a transformation in American medicine. ... [D]octors like him are increasingly being replaced by teams of rotating doctors and nurses who do not know their patients nearly as well. A centuries-old intimacy between doctor and patient is being lost.
Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced interim data from a 12-week phase IIb clinical trial of IDX184, the Company's lead product candidate for the treatment of hepatitis C virus (HCV) infection.
Every principal investigator (PI) who uses laboratory animals in his or her research now can benefit from a new monthly independent source of expert advice in complying with government and institutional rules and ethics guidelines. That's the purpose of the new subscription newsletter, Laboratory Animal Welfare Compliance.
› Verified 9 days ago
| Entity Name | Onsite Health Specialty Physicians, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265024194 PECOS PAC ID: 1850708892 Enrollment ID: O20210318001615 |
News Archive
Heart attack patients given a combination of high-dose oral vitamins and minerals do not exhibit a significant reduction in recurrent cardiac events, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
The report by scientists of a new hepatitis virus earlier this year was a false alarm, according to UC San Francisco researchers who correctly identified the virus as a contaminant present in a type of glassware used in many research labs.
Dr. [Ronald] Sroka has practiced family medicine for 32 years in a small, red-brick building just six miles from his childhood home. ... Dr. Sroka, 62, thought about retiring. He tried to sell his once highly profitable practice. No luck. He tried giving it away. No luck. Dr. Sroka's fate is emblematic of a transformation in American medicine. ... [D]octors like him are increasingly being replaced by teams of rotating doctors and nurses who do not know their patients nearly as well. A centuries-old intimacy between doctor and patient is being lost.
Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced interim data from a 12-week phase IIb clinical trial of IDX184, the Company's lead product candidate for the treatment of hepatitis C virus (HCV) infection.
Every principal investigator (PI) who uses laboratory animals in his or her research now can benefit from a new monthly independent source of expert advice in complying with government and institutional rules and ethics guidelines. That's the purpose of the new subscription newsletter, Laboratory Animal Welfare Compliance.
› Verified 9 days ago
| Entity Name | Advanced Woundcare, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447821459 PECOS PAC ID: 3678971389 Enrollment ID: O20211011002662 |
News Archive
Heart attack patients given a combination of high-dose oral vitamins and minerals do not exhibit a significant reduction in recurrent cardiac events, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
The report by scientists of a new hepatitis virus earlier this year was a false alarm, according to UC San Francisco researchers who correctly identified the virus as a contaminant present in a type of glassware used in many research labs.
Dr. [Ronald] Sroka has practiced family medicine for 32 years in a small, red-brick building just six miles from his childhood home. ... Dr. Sroka, 62, thought about retiring. He tried to sell his once highly profitable practice. No luck. He tried giving it away. No luck. Dr. Sroka's fate is emblematic of a transformation in American medicine. ... [D]octors like him are increasingly being replaced by teams of rotating doctors and nurses who do not know their patients nearly as well. A centuries-old intimacy between doctor and patient is being lost.
Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced interim data from a 12-week phase IIb clinical trial of IDX184, the Company's lead product candidate for the treatment of hepatitis C virus (HCV) infection.
Every principal investigator (PI) who uses laboratory animals in his or her research now can benefit from a new monthly independent source of expert advice in complying with government and institutional rules and ethics guidelines. That's the purpose of the new subscription newsletter, Laboratory Animal Welfare Compliance.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mark Bernard Lubienski, MD 372 Red Bud Ct, Frankfort, IL 60423-2128 Ph: (708) 710-6048 | Dr Mark Bernard Lubienski, MD 372 Red Bud Ct, Frankfort, IL 60423-2128 Ph: (708) 710-6048 |
News Archive
Heart attack patients given a combination of high-dose oral vitamins and minerals do not exhibit a significant reduction in recurrent cardiac events, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
The report by scientists of a new hepatitis virus earlier this year was a false alarm, according to UC San Francisco researchers who correctly identified the virus as a contaminant present in a type of glassware used in many research labs.
Dr. [Ronald] Sroka has practiced family medicine for 32 years in a small, red-brick building just six miles from his childhood home. ... Dr. Sroka, 62, thought about retiring. He tried to sell his once highly profitable practice. No luck. He tried giving it away. No luck. Dr. Sroka's fate is emblematic of a transformation in American medicine. ... [D]octors like him are increasingly being replaced by teams of rotating doctors and nurses who do not know their patients nearly as well. A centuries-old intimacy between doctor and patient is being lost.
Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced interim data from a 12-week phase IIb clinical trial of IDX184, the Company's lead product candidate for the treatment of hepatitis C virus (HCV) infection.
Every principal investigator (PI) who uses laboratory animals in his or her research now can benefit from a new monthly independent source of expert advice in complying with government and institutional rules and ethics guidelines. That's the purpose of the new subscription newsletter, Laboratory Animal Welfare Compliance.
› Verified 9 days ago
Dr. Marshall Edward James Jr., MD General Practice Medicare: Accepting Medicare Assignments Practice Location: 20180 S Lagrange Rd, Frankfort, IL 60423 Phone: 815-464-2010 Fax: 815-464-2181 |